Shares of PLx Pharma Inc (NASDAQ:PLXP) have received an average broker rating score of 2.00 (Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating.

Analysts have set a 12 month consensus price objective of $12.00 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also given PLx Pharma an industry rank of 169 out of 265 based on the ratings given to its competitors.

A number of analysts have recently commented on PLXP shares. Zacks Investment Research cut shares of PLx Pharma from a “buy” rating to a “sell” rating in a report on Tuesday, October 3rd. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a report on Monday, December 4th.

Shares of PLx Pharma (NASDAQ:PLXP) traded down $0.35 during mid-day trading on Friday, hitting $6.65. 3,212 shares of the stock were exchanged, compared to its average volume of 5,383. PLx Pharma has a 1 year low of $5.60 and a 1 year high of $13.20. The company has a market cap of $61.27, a PE ratio of -1.32 and a beta of 1.82. The company has a current ratio of 8.99, a quick ratio of 8.88 and a debt-to-equity ratio of 0.56.

A hedge fund recently bought a new stake in PLx Pharma stock. Harel Insurance Investments & Financial Services Ltd. purchased a new position in PLx Pharma Inc (NASDAQ:PLXP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 250,000 shares of the biotechnology company’s stock, valued at approximately $145,000. Harel Insurance Investments & Financial Services Ltd. owned about 2.88% of PLx Pharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

About PLx Pharma

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.